🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-522742-46-00
Authorised Phase IV

CANIDIAP; CANagliflozin In DIAlysis Patients

2025-522742-46-00 · tracked via the Priya Life Science EU tracker
Sponsor
Universitair Medisch Centrum Groningen
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Not possible to specify
Decision date
23/02/2026
Enrollment target
10
Sites
Netherlands

Condition studied

Chronic Kidney disease

Investigational medicinal product(s)

18F-CanagliflozinInvokana 300 mg film-coated tablets

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male

Primary endpoint

The overall percentage of receptor occupancy.

Endpoint detail

The percentage of receptor occupancy in the specific regions of interest., The overall percentage of receptor occupancy compared between dialysis patients that have and that do not have residual diuresis.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522742-46-00 on CTIS ↗ ← All trials in the EU